Cancer – basic facts

- Pathological process (disease) due to **impaired control of cell cycle** and thus cell division
  - if genes that control the orderly cell replication become damaged it allows the cell to reproduce without restraint
  - it might eventually spread into neighbouring tissues and set up secondary growths throughout the body (**metastases**)
  - the reason for this dys-regulation is genetic – mutations of originally just 1 **somatic cell** (but also germinative in some cases)
    - tumor classification according to the growth rapidity
      - benign – grow only in the site of origin, not aggressive, maintain differentiation
      - malignant – rapid growth, invasive, spreading to other places, undifferentiated
    - All types of cancers are due to **genetic alteration** of key genes controlling cell cycle
      - however, only a few are inherited at the same time (i.e. **familial**) = due to the mutation in germinative cell
      - majority of cancers are due to the acquired genetic changes during the life (i.e. **sporadic**) = due to the mutation in somatic cell
    - Key genes controlling cell cycle
      - **(proto)oncogens** – genes that normally potentiate cell division and growth under the physiologic stimuli, if mutated process becomes uncontrolled
      - **suppressor genes** – genes that normally inhibit cell division, if mutated growth becomes uncontrolled
      - **DNA reparation genes** – genes encoding enzymes that can repair reparable DNA damage occurring due to the environmental or endogenous agents (e.g. UV light, oxygen radicals), if mutated unrepaired alteration can be transmitted into daughter cells

Cell cycle (CC)

- most of the somatic cells grows, double the amount of cell organelles and divide = cell cycle
- CC (4 phases)
  - interphasis
    - cell growth (G1-phase)
    - DNA replication (S-phase)
    - additional growth (G2-phase)
  - mitosis (M-phase)
- duration of CC is very variable in different cell types
  - hours in enterocytes
  - months in liver cells
  - life time in neurons (in G0-phase)
- G1-phase has the most variable length
  - CC is naturally inhibited in G1 (growth arrest)
    - by contact inhibition
    - by products of suppressor genes
  - CC is highly regulated by very often counteracting
    - internal factors – e.g. inhibition by suppressor proteins
    - external factors – e.g. stimulation by growth factors
- cancer = dysregulation of CC
- cell cycle carries on only if
  - all phases proceed without errors
    - 3 check-points
  - energy is available
  - external stimuli (growth factors) are acting
**CC phases**

<table>
<thead>
<tr>
<th>Phase</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>G0</td>
<td>Resting phase. Cell perform its function, maintain basal metabolism and does not divide.</td>
</tr>
<tr>
<td>G1</td>
<td>Interval between previous Mitosis and subsequent Synthesis (= DNA replication). Intensive synthesis of all sorts of RNAs in the nucleus. Proteosynthesis in the cytoplasm and overall cell growth. G1 duration basically determines the CC length. <strong>G1 check point</strong> (= favourable conditions and energy supply)</td>
</tr>
<tr>
<td>S</td>
<td>DNA replication in the nucleus and histone synthesis in the cytoplasm. At the end the cell contains doubled the amount of DNA.</td>
</tr>
<tr>
<td>G2</td>
<td>Interval between previous Synthesis and subsequent Mitosis. Cell further grows and proteosynthesis (mainly tubulin and other proteins necessary for mitotic apparatus). <strong>G2 check point</strong> (= completeness and correctness of DNA replication)</td>
</tr>
<tr>
<td>M</td>
<td>Mitosis (6 phases) – first 5 (prophasis, prometaphasis, metaphasis, anaphasis, telophasis) represent division of nucleus, the last one (cytokinesis) division of the whole cell. <strong>M check point</strong> (= correct formation of mitotic spindle in metaphasis/anaphasis transition)</td>
</tr>
</tbody>
</table>

---

**CC check points and mitosis**

- **Interphase**: All Chromosomes
- **Prophase**: Chromosomes start to be visible
- **Prometaphase**: Nucleus is disorganised and membrane of centriomeres
- **Metaphase**: Chromosomes align on a plane of cell
- **Anaphase**: Segregated chromosomes are pulled apart
- **Telophase**: New nucleus is dispersed and cleavage forms
- **Cytokinesis**: Two daughter cells formed each with 40 chromosomes

---

**CC regulatory proteins**

- **(A) products of (proto)oncogenes**
  - cyclins
  - cyclin-dependent proteinkinases (cdk)
  - growth factors
  - receptors for growth factors
  - G-proteins
  - membrane tyrosine kinases (e.g. abl)
- **(B) products of suppressor genes**
  - Rb
  - p53
  - p21
- **(C) products of genes encoding DNA repair enzymes**
  - mismatch repair
  - excision repair
  - homologous recombination

---

**A) - Protooncogenes**

- **(1) cyclins**
  - 8 types – A, B, C, D, E, F, G, H
  - specific for particular CC phases
- **(2) cyclin-dependent kinases (cdk)**
  - 9 types – cdk1 to cdk9
    - only complex of cdk with cyclin is active
    - activate target proteins by phosphorylation of Ser and Thr
      - e.g. Rb-protein
    - normally present in the complex
      - cyclin
      - cdk
      - PCNA (Proliferating Cell Nuclear Antigen)
    - cdk inhibitor (e.g. p21, p27, ...)
    - proteolysis of the inhibitors allows the complex being active
    - levels of cdk maintain relatively stable throughout the CC while expression of cyclins differs
      - expressed under the stimulation with growth factors
      - degraded by ubiquitin-proteasome proteolysis
(A) Protooncogenes

- **(3) growth factors (GF)**
  - e.g. TGF-β, PDGF, EGF, FGF, VEGF, erythropoetin, ...
  - GF acts in extremely low concentrations in paracrine fashion
  - different target cells according to the expression of specific receptors

- **(4) GF receptors**
  - receptors with tyrosinkinase activity
  - transduction cascade
    - downstream kinases (MAPK – Mitogen Activated Protein Kinase)
    - transcription of early–response genes (~15 min) = **(5) transcription factors**
      - e.g. regulatory proteins fos, jun a myc (= products of protooncogens fos, jun and myc)
    - transcription of late–response genes (~1 hrs)
      - expression of cyclins and cdk under the stimulation with fos, jun, myc regulatory proteins

(B) - Suppressor genes

- encode inhibitory proteins of CC
  - **(1) Rb protein** (ch. 13q14)
    - principal negative regulator of CC, controls the G1-S-phase transition, activity modulated by de-phosphorylation (by cdk4/6 + cyclin D complex)
    - mutations in Rb (microdeletions) predispose to the retinoblastoma
  - **(2) p53 protein** (ch. 17p13)
    - "guardian of the genome" – active in G1 and G2 checkpoints
    - DNA damage increases expression of p53
    - act as a transcription factor for DNA repair and apoptosis genes
  - **(3) p21**
    - main target of p53 = inhibitor of Cdk – CC arrest in G1 phase by inhibition of Cdk2/cyclin E complex
  - **(4) BRCA1 and BRCA2**
    - part of DNA damage detection system
  - inherited mutations in suppressor genes can confer susceptibility to the inherited (familiar) forms of cancer
    - very often named according to the type of tumor developing due to their mutation
      - Rb (= retinoblastoma)
      - WT (= Wilm's tumor)
      - NF1 and NF2 (= neurofibromatosis)
      - APC (= Adenomatous Polyposis Coli)
      - DCC (= Deleted in Colon Cancer)
      - VHL (= von Hippel-Lindau syndrome)
Rb protein (Rb/E2F G\textsubscript{1} checkpoint)

- Rb is a main inhibitor/regulator of CC
  - binding to the transcription factor E2F, which upon release from Rb ↑ expression of S-phase genes (e.g. DNA replication enzymes, PCNA, ...)
- Rb controls the transition from G1- to S-phase
- Rb is present all the time, however, its activity is modulated by de-/phosphorylation by MAPK/cdk pathways
  - phosphorylated Rb = inactive
  - dephosphorylated Rb = active

Rb protein - retinoblastoma

- Rb mutations (ch. 13q14) – most often microdeletions - lead to retinoblastoma (tumor of retina)
  - (1) inherited (familiar) from of retinoblastoma
    - patient inherited one mutated allele, second one is mutated early during the life (= loss of heterozygosity, LOH)
  - (2) acquired (sporadic) retinoblastoma
    - inactivation Rb by mutation of both alleles anytime during the life

Development of sporadic retinoblastoma by LOH mechanism

- Partial summary – CC “kick-off”
  - mitogens drive CC progression by induction of cyclin D and inactivation of the retinoblastoma (Rb) protein
    - CC is driven by the co-ordinated activation of CDKs (expressed throughout the CC) and their activating subunits – the cyclins (oscillating between rapid synthesis and degradation)
    - the interface between mitogens and the cell cycle is cyclin D (and to a lesser extent cyclin E), whose expression is induced by mitogens
    - cyclin D- and cyclin E-dependent kinases phosphorylate (P) and thereby disable the Rb tumour suppressor protein, which is a principal checkpoint controlling the progression from G2 to S phase
    - inactivation of the Rb protein marks the restriction point at which cell-cycle progression becomes independent of mitogens
      - inactivated Rb releases E2F transcription factors, which stimulate the expression of downstream cyclins and other genes that are required for DNA synthesis
Protein p53 (ch. 17p13)

- main controller of genome stability
- if DNA is mutated or incompletely replicated p53 becomes activated and:
  - ↑ expression of CC inhibitors → temporary CC arrest in G1/S check point enabling DNA reparation ("major repair")
    - (CIP1/WAF1 gene → p21 protein)
  - ↑ GADD 45 (Growth Arrest and DNA Damage) → DNA excision repair
    - Bax expression → apoptosis
- p53 mutations are the most frequent genetic abnormality found in human cancer
  - ~50% of all cancers!!!
- there are also some familiar forms of cancer due to inherited p53 heterozigous mutations
  - LOH mechanism

Apoptosis

Apoptosis-initiating pathways

(C) - DNA repair (stability) genes

- (1) MMR genes/proteins ("Mismatch repair")
  - enzymes can repair erroneous base pair
  - defect in respective genes leads to the microsatellite length instability (MLI)
    - variable length of microsatellites (e.g., (CA)n repetition) leads to the DNA replication errors
    - example is HNPCC (Hereditary Non-Polyposis Colon Cancer)
- (2) excision repair (double strand break)
  - (3) genes of homologous recombination
    - main pathway activated on DNA damage (double strand break) involves: ATM (ATR)/CHK2 (CHK1) → p53/MDM2 → p21 → "growth arrest"
  - inborn defects lead to several forms of familiar cancers
    - ataxia telangiectatica
    - Bloom syndrome
    - Fanconi anemia
    - xeroderma pigmentosum
    - fragile X syndrome
Other factors influencing CC
- contact inhibition
- anchoring
- intercellular communication
  - integrins, cadherins

Changes in adhesion during the metastatic process
- cancer cells lose E-cadherin-dependent intercellular adhesions, acquire a migratory phenotype, penetrate the basement membrane, and invade the interstitial matrix. Tumour angiogenesis then allows cancer cells to enter the bloodstream, either directly or through the lymphatic system, by a process called intravasation. In the circulation, tumour cells form small aggregates with platelets and leukocytes. Finally, after stopping in the microcirculation of the target organ, tumour cells exit the bloodstream, by a process called extravasation, and undergo local expansion.

Malignant transformation
- multistage process of subsequent changes of genome - mutations in the critical DNA region (usually 4 - 6)
  - chromosomal aberrations
    - translocation, insertion, deletion, amplification
  - gene mutations
    - point mutations
    - length mutations (ins/del)
- effect of mutation
  - change of transcription - quantitative effect
  - synthesis of altered product - qualitative effect
- mutagens/carcinogens
  - physical
    - UV light (skin carcinoma and basaloma, melanoma)
    - ionising radiation and X-rays (leukaemia, thyroid gland, bones, ...)
  - chemical
    - polycyclic aromatic and chlorated hydrocarbons, aromatic amines, nitrosamines, heavy metals, mycotoxins, ...
    - GIT cancer as a result of dietary toxins exposure
    - lung cancer as a result of smoking
    - alcoholic liver cirrhosis
  - biological = incorporation of viral genome into the host one in critical regions
    - DNA viruses
      - herpes/EBV - lymphomas
      - HBV - hepatocellular ca
      - HPV - cervical ca, larynx, oral cavity
    - RNA viruses
      - HIV - Kaposi sarcoma, B-lymphoma
      - HTLV - T-cell leukaemia
  - pre-cancerosis = chronic inflammation
    - Barrett’s oesophagus in GER, ulcerative colitis and Crohn’s disease, diverticulitis, ...

Partial summary
- 3 groups of genes contribute to the malignant transformation
  - protooncogenes (POG)
  - suppressor genes (TS)
  - DNA stability genes (SG)
  - not immediately involved in the tumorigenesis, but lack of their function leads to the higher mutation rate in general incl. POG and TS
Cancer

- autonomously proliferating tissue genetically altered by exposure to carcinogens
- originate from 1 cell (= monoclonal)
- the whole process of malignant transformation is however multistage (i.e. subsequent accumulation of several mutations), so the tumor gradually becomes genetically heterogeneous
  - transition from precancerous - benign to malignant tumor
- histologically 3 groups:
  - epithelial - skin, mucous membranes, duodenum
  - mesenchymal - connective tissue, endothelium, muscle, haematopoietic and lymphatic tissue, bone,
  - neuroectodermal - CNS and peripheral nerves, pigment nevi
- tumor classification:
  - morphologic = typing = histological type
  - invasivity = grading = benign × malignant
  - initial extent = staging = TNM classification (T = tumor, N = node, M = metastasis)

Tumor growth kinetics

- cell divisions in the clone of tumor cells: N=2^n
  - 2, 4, 8, 16, 32, .......
    - 10 divisions = ~1,000 cells
    - 20 divisions = ~1,000,000 cells (m=1mg)
    - 30 divisions = ~1,000,000,000 cells (m=1g)
    - 40 divisions = m=1kg
- given ~12-hr cell cycle in approx. 20 days
- in reality the growth is much more slower due to death of variable proportion of tumor cells and other factors:
  - prolongation of cell cycle duration
  - non-proliferating fraction of cells (differentiated)
  - tumor cell death (malnutrition, cytotoxic lymphocytes, NK cells)
  - mechanic loss of cells (desquaming e.g. in intestine)
- tumor grows only after formation of stroma and capillary network (= angiogenesis)
  - in that case growth overbalance the loss of cells

Tumor growth - angiogenesis

- ↑ cell proliferation/↓ cell death in tumor
  - need for energy (oxygen and substrates)
  - as a response to hypoxia hypoxia-inducible factor-1 (HIF-1) is produced
  - HIF-1 has 2 subunits - hydroxylation of HIF-1a (under the normoxia conditions leads to the rapid degradation)
  - under the hypoxia conditions HIF-1a migrates to the nucleus, binds to HIF-1b and HIF-1 complex functions as a transcription factor
  - after the translocation into nucleus HIF-1a stimulates transcription of many genes, e.g. vascular endothelial growth factor (VEGF)
  - VEGF stimulate formation of new vessels (angiogenesis)
  - proteolytic enzymes produced by tumor (matrix metallopeptinases) degrade extracellular matrix and enable "budding" of new vessels from the existing ones
  - proliferation and migration of endothelial cells is further potentiated by angiogenic factors secreted by tumor (e.g. VEGF, basic fibroblast growth factor (bFGF), transforming growth factor-b (TGF-b), and platelet-derived growth factor (PDGF)
  - new vessels enable invasion of tumor cells into circulation and distant metastases

Tumor growth vs. tumor

- tumor cells has several immunological abnormalities
  - quantitative changes in the expression of surface antigens (1-HMC)
  - tumor cells thus escape immune recognition and destruction
  - qualitative - expression of neo-antigens ("oncofetal")
  - diagnostic markers (e.g. CEA, α-fetoprotein etc.)
- cytotoxic mechanisms are a major tool of anti-tumor immunity
  - CD8+ T-lymphocytes – NK-cells
- although immune system on its own is not powerful enough to seal with advanced tumor, the role of immunity in the anti-tumor surveillance is very important
  - people with immunosuppression has a high rate of cancer
    - e.g. Burkitt’s lymphoma in Central Africa (malaria)
Hypoxia-induced gene transcription

Hormonal stimulation

- growth of some tumors is significantly potentiated by hormones, typically by sex hormones
  - breast, uterus, ovary, prostate

Metastasizing

- formation of daughter tumors distant from original site
- several ways of spreading
  - blood
    - very often in the direction of flow
      - from GIT to the liver
      - by venous blood to the lungs
      - from lungs by artery blood to bones and brain
  - lymphatic
    - first neighbouring lymph nodes, than distant

Example – colorectal carcinoma
Interaction of tumor with the host

- local effect of tumor
  - mechanical compression (e.g. brain tumors)
  - obstruction (e.g. de. choledochus)
  - bleeding, anemia (leukaemia)
- chronic blood losses into GIT (gastric and intestinal tumors)
- oedema (e.g. lymphomas)
- thromboses (DIC)
- loss of vision (compression of optic nerve by hypophyseal adenoma)
- voice change (laryngeal ca)
- coughing (lung ca)
- difficult swallowing (oesophageal ca)
- pathological fractures (myeloma)

- systemic effects
  - increased temperature/unexplained fever
  - production of cytokines (pyrrogens) by tumor (IL-1, TNFα)
  - tumor cachexia
- anorexic mediators (TNFα)
- paraneoplastic syndromes
  - some tumors produce hormones (adenomas) – important diagnostically!
    - pigmentation
    - endokrinopathy
  - Cushing sy, hypercalcaemia, etc.
- secondary effects (energy deprival, obstruction, treatment side-effects)
  - oedema (e.g. lymphomas)
  - thromboses (DIC)
  - loss of vision (compression of optic nerve by hypophyseal adenoma)
  - voice change (laryngeal ca)
  - coughing (lung ca)
  - difficult swallowing (oesophageal ca)
  - pathological fractures (myeloma)

Tumor anorexia / cachexia

- initial anorexia might be a part of non-specific defence mechanisms (energetic deprivation of growing tumor)
  - gradually it becomes a part of progressive cachexia and further compromise self-defence
  - i.e. tumor cachexia is an end-result of tumor anorexia and secondary effects (energy deprival, obstruction, treatment side-effects)
- initial tumor anorexia (also experimentally inducible - TNFα) is different from nausea and sickness as a side-effect of treatment (e.g. brain tumors)
- paraneoplastic syndromes
  - energetic requirements of growing tumor are increased and gradually if becomes advert complication leading to progressive cachexia and further compromise oh self-defence

- energetic requirements of growing tumor are increased and compromise other organs
- pathophysiology of tumor anorexia/cachexia
  - altered activation of regulatory centres in hypothalamus regulating food intake (n. arcuatus) due to cytokines produced by tumor or by the host’s immune system (IL-1, IL-6, TNF-α)
  - cytokines stimulate release of serotonin and thus persistent activation of POMC/CART neurons
  - concentrated NPY (orexigenic) and, conversely, over-activation of system POMC/CART (anorexigenic)

<table>
<thead>
<tr>
<th>Syndrome</th>
<th>Major tumor types</th>
<th>Mode of inheritance</th>
<th>Type of gene</th>
<th>Genes</th>
</tr>
</thead>
<tbody>
<tr>
<td>Adenomatous polyposis of the colon</td>
<td>Colon, thyroid, stomach, intestine, hepatoblastoma</td>
<td>Dominant</td>
<td>TS</td>
<td>APC</td>
</tr>
<tr>
<td>Juvenile polyposis</td>
<td>Gastrointestinal</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Peutz-Jeghers syndrome</td>
<td>Intestinal, ovarian, pancreatic</td>
<td>Dominant</td>
<td>TS</td>
<td>SMAD4/DPC4</td>
</tr>
<tr>
<td>Neurofibromatosis type 1</td>
<td>Neurofibroma, optic pathway glioma, peripheral nerve sheath tumor</td>
<td>Dominant</td>
<td>TS</td>
<td>NF1</td>
</tr>
<tr>
<td>Neurofibromatosis type 2</td>
<td>Vestibular schwanoma</td>
<td>Dominant</td>
<td>TS</td>
<td>NF2</td>
</tr>
<tr>
<td>Tuberous sclerosis</td>
<td>Hamartoma, renal angiomyolipoma, renal cell carcinoma</td>
<td>Dominant</td>
<td>TS</td>
<td>TSC1/TSC2</td>
</tr>
<tr>
<td>Xeroderma pigmentosum</td>
<td>Skin, melanoma, leukemia</td>
<td>Recessive</td>
<td>SG</td>
<td>XPA, B, C, D, E, F, G, POLH</td>
</tr>
<tr>
<td>Bloom syndrome</td>
<td>Leukemia, lymphoma, skin</td>
<td>Recessive</td>
<td>SG</td>
<td>BLM</td>
</tr>
<tr>
<td>Fanconi anemia</td>
<td>Leukemia, squamous cell carcinoma, gynaecological system</td>
<td>Recessive</td>
<td>SG</td>
<td>FAANA, B, C, D, E, F, G</td>
</tr>
<tr>
<td>Nijmegen breakage syndrome</td>
<td>Lymphoma, medulloblastoma, glioma</td>
<td>Recessive</td>
<td>SG</td>
<td>NBS1</td>
</tr>
<tr>
<td>Ataxia telangiectasia</td>
<td>Leukemia, lymphoma</td>
<td>Recessive</td>
<td>SG</td>
<td>ATM</td>
</tr>
<tr>
<td>Von Hippel-Lindau syndrome</td>
<td>Retinal and central nervous</td>
<td>Recessive</td>
<td>SG</td>
<td>VHL</td>
</tr>
<tr>
<td>hemangioblastoma, pheochromocytoma, renal cell carcinoma</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Wilms tumor syndrome</td>
<td>Wilms tumor</td>
<td>Dominant</td>
<td>TS</td>
<td>WT1</td>
</tr>
<tr>
<td>Retinoblastoma</td>
<td>Retinoblastoma, osteosarcoma</td>
<td>Dominant</td>
<td>RS</td>
<td>RB1</td>
</tr>
<tr>
<td>Li-Fraumeni syndrome</td>
<td>Soft tissue sarcoma, osteosarcoma, breast, adrenocortical carcinoma, leukemia, brain tumor</td>
<td>Dominant</td>
<td>TS</td>
<td>TP5</td>
</tr>
<tr>
<td>Multiple exostosis</td>
<td>Chondrosarcoma</td>
<td>Dominant</td>
<td>TS</td>
<td>EXT1/EXT2</td>
</tr>
<tr>
<td>Werner syndrome</td>
<td>Osteosarcoma, menignoma</td>
<td>Recessive</td>
<td>SG</td>
<td>WRN</td>
</tr>
<tr>
<td>MEN 1</td>
<td>Pancreatic islet cell tumor, pituitary adenoma, parathyroid adenoma</td>
<td>Dominant</td>
<td>TS</td>
<td>MEN1</td>
</tr>
<tr>
<td>MEN 2</td>
<td>Medullary thyroid carcinoma, pheochromocytoma, parathyroid hyperplasia</td>
<td>Dominant</td>
<td>OG</td>
<td>RET</td>
</tr>
</tbody>
</table>

TS - tumor suppressor gene; OG - oncogene; SG - stability gene; OMIM - online Mendelian inheritance in man